Alexandria®
World's largest body of medical evidence for clinical decision support and LLM training
Platform · Cloud SaaSCompany source
Company profile
About Atropos Health
Atropos Health is a healthcare AI company that addresses the critical 'Evidence Gap' in medicine—where only 14% of daily medical decisions are backed by high-quality evidence. The company has developed Alexandria®, the world's largest body of medical evidence containing over 33 million precision Evidence-Based Findings (pEBF™), expected to scale to two billion studies by 2026. Atropos Health's platform combines advanced AI technology, comprehensive data access, and automated tools to generate publication-grade Real-World Evidence in minutes rather than months. Their solutions serve multiple healthcare stakeholders including health systems, pharmacy departments, life sciences companies, and research institutions. The company's flagship products include ChatRWD® for conversational evidence queries, Green Button® for automated study generation, Forge® for data analysis, and the Atropos Evidence™ Agent for AI-powered clinical decision support. Built on the GENEVA OS® platform, Atropos Health has achieved a 100% success rate in publishing studies in peer-reviewed journals including Cell and NEJM Catalyst, with over 50 publications and 10,000+ clinical questions converted into studies. The company has helped clients save over $100 million through expedited analytics, optimized formulary decisions, and improved care management. Atropos Health partners with leading organizations including Stanford Health Care, Emory Healthcare, University of Michigan, and Databricks to fulfill the promise of data-driven, evidence-based medicine for individual patients.
Company description Atropos Health official website
Primary marketGenerative AI & Healthcare Infrastructure
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Atropos Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- COVID-19 inpatient care
- Inflammatory Bowel Disease (IBD)
- Mental Health
- Obstetric Anesthesia
- Radiation Oncology
- Surgical Oncology
- Type 2 Diabetes
Who it serves
- Academic Medical Centers
- Health Systems
- Life Sciences Companies
- Payers
- Pharmacy Departments
- Research Institutions
Deployment & integration
Api Only · Cloud Saas deployment with recorded integration context.
Recorded integration context: Databricks.
Geographic context
MarketsUSA
Company sourceOfficial website
Company milestones
Platform expansion
Launched Alexandria® as world's largest body of medical evidence with 33M studies (2024-2025); Expanded partnership with Databricks launching Atropos Evidence Agent MCP on Databricks Marketplace; Scaling to 2 billion studies by end of 2026
Partnerships
Recorded partners
- Chan Zuckerberg Biohub
- Databricks
- Emory Healthcare
- Prisma Health
- Stanford Health Care
- University of Michigan
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Atropos Evidence™ Agent
AI agent for evidence-backed clinical answers within Databricks
Api · Api OnlyCompany source
Atropos Evidence™ Network
Network of real-world data sources with quality scoring
Platform · Cloud SaaSCompany source
ChatRWD®
Conversational interface for real-world data evidence generation
Software · Cloud SaaSCompany source
Forge®
Evidence generation and analysis tool
Software · Cloud SaaSCompany source
GENEVA OS®
Operating system for real-world evidence generation
Platform · Cloud SaaSCompany source
Green Button®
Rapid evidence generation automation tool
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Sodium Glucose Co-Transporter 2 Inhibitors Use in Diabetic Patients with Cirrhosis Improves Liver-related Outcomes and Survival.Clinical and translational gastroenterology · Aug 6, 2026
Healthcare Utilization After Biologic Initiation for Chronic Rhinosinusitis.American journal of rhinology & allergy · Aug 5, 2026
The Influence of Preoperative Mood Disorders on Postoperative Complications and Healthcare Utilization in Adolescent Sports Injuries.Sports health · Jul 23, 2026
Antibiotic Prophylaxis in Prepectoral Alloplastic Breast Reconstruction: Establishing Standards.Plastic and reconstructive surgery · Jul 14, 2026
Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.Journal of hospital medicine · Jun 1, 2026
Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.Alimentary pharmacology & therapeutics · Jun 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
$100M+ saved by clients
Through expedited analytics, maximized RWD assets, medication cost savings, patient throughput and care management programs
10,000+ clinical questions converted to studies
Publication-grade observational studies run on behalf of clients
100% publication success rate
All studies successfully published in peer-reviewed journals
33 million precision Evidence-Based Findings
Alexandria® library growing to 2 billion studies by 2026
Emory Healthcare
Formulary management and clinical pharmacy services
Prisma Health
Digital health implementation with rapid time to value - access to evidence and insights on local data
Benefits realized on day one with access to hundreds of millions of patient records and thousands of novel studies
Stanford Health Care
Formulary management - evaluated medications for formulary consideration using Real World Evidence to understand patient outcomes
Resulted in removal or restriction of medications from formulary based on RWE findings
Stanford University (Gastroenterology)
Clinical research and academic presentations using Real World Evidence for gastroenterology questions
Presentation selected as finalist for 'Best of DDW' at Digestive Disease Week conference
University of Michigan
Evidence-based surgical care decision support
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Atropos Health
Recent articles published on Atropos Health's official website.
Impact of JAK Inhibitors on Liver Biochemistries in Patients with Coexisting Autoimmune Hepatitis
Read on Atropos HealthUsing Machine Learning and Real-World Data to Identify Patients with Schizophrenia for whom Aripiprazole Monohydrate LAIs are Likely to be a Favorable Treatment Option
Read on Atropos HealthContinuation Versus Discontinuation of Beta-Blockers During Hospitalisation for Viral Pneumonia in Patients with COPD and HFrEF
Read on Atropos HealthAssociation Between Selective Serotonin Reuptake Inhibitor Use and Outcomes in Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
Read on Atropos HealthAtropos Health CMO and Co-Founder Dr. Saurabh Gombar on Closing the Evidence Gap in Clinical Care
Read on Atropos Health07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Generative AI & Healthcare Infrastructure
Companies providing generative AI platforms, large language models (LLMs), foundation models, or broad AI infrastructure specifically designed for healthcare applications. These companies serve multiple clinical use cases across the health system rather than focusing on a single clinical application or disease area.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.